Goldman Sachs Group Inc Athenex, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.12 - $0.21 $5,388 - $9,429	-44,902 Reduced 80.76%	10,695 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.12 - $0.21 $5,388 - $9,429	-44,902 Reduced 80.76%	10,695 $1,000
Q3 2022 May 14, 2024	SELL	$0.24 - $1.11 $51,276 - $237,152	-213,651 Reduced 79.35%	55,597 $15,000
Q3 2022 Nov 10, 2022	SELL	$0.24 - $1.11 $51,276 - $237,152	-213,651 Reduced 79.35%	55,597 $0
Q2 2022 May 14, 2024	BUY	$0.41 - $0.91 $110,391 - $245,015	269,248 New	269,248 $110,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $0.91 $47,110 - $104,561	114,903 Added 74.45%	269,248 $110,000
Q1 2022 May 16, 2022	SELL	$0.79 - $1.59 $118,965 - $239,436	-150,589 Reduced 49.38%	154,345 $128,000
Q4 2021 Feb 14, 2022	BUY	$1.36 - $2.94 $112,905 - $244,075	83,019 Added 37.41%	304,934 $414,000
Q3 2021 Nov 10, 2021	BUY	$2.97 - $4.84 $659,087 - $1.07 Million	221,915 New	221,915 $668,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.